Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3389/fphar.2017.00326 http://scihub22266oqcxt.onion/10.3389/fphar.2017.00326 C5447768!5447768!28611671     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Front+Pharmacol 2017 ; 8 (ä): ä Nephropedia Template TP {{tp|p=28611671|t=2017. Targeting Hypoxia Inducible Factors-1? As a Novel Therapy in Fibrosis |pdf=|usr=}}{{28611671}} gab.com Text Targeting Hypoxia Inducible Factors-1 As a Novel Therapy in Fibrosis JO: Front Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=28611671 #FOAvip Fibrosis, characterized by increased extracellular matrix (ECM) deposition, and widespread vasculopathy, has the prominent trait of chronic hypoxia. Hypoxia inducible factors-1? (HIF-1?), a key transcriptional factor in response to this chronic hypoxia, is involved in fibrotic disease, such as Systemic sclerosis (SSc). The implicated function of HIF-1? in fibrosis include stimulation of excessive ECM, vascular remodeling, and futile angiogenesis with further exacerbation of chronic hypoxia and deteriorate pathofibrogenesis. This review will focus on the molecular biological behavior of HIF-1? in regulating progressive fibrosis. Better understanding of the role for HIF-1?-regulated pathways in fibrotic disease will accelerate development of novel therapeutic strategies that target HIF-1?. Such new therapeutic strategies may be particularly effective for treatment of the prototypic, multisystem fibrotic, autoimmune disease SSc. Twit Text FOAVip Targeting Hypoxia Inducible Factors-1 As a Novel Therapy in Fibrosis ????Front Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=28611671 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28611671 #FOAvip English Wikipedia <ref>{{Cite pmid|28611671}}</ref> Targeting Hypoxia Inducible Factors-1? As a Novel Therapy in Fibrosis #MMPMID28611671 Xiong A; Liu Y Front Pharmacol 2017[]; 8 (ä): ä PMID28611671show ga Fibrosis, characterized by increased extracellular matrix (ECM) deposition, and widespread vasculopathy, has the prominent trait of chronic hypoxia. Hypoxia inducible factors-1? (HIF-1?), a key transcriptional factor in response to this chronic hypoxia, is involved in fibrotic disease, such as Systemic sclerosis (SSc). The implicated function of HIF-1? in fibrosis include stimulation of excessive ECM, vascular remodeling, and futile angiogenesis with further exacerbation of chronic hypoxia and deteriorate pathofibrogenesis. This review will focus on the molecular biological behavior of HIF-1? in regulating progressive fibrosis. Better understanding of the role for HIF-1?-regulated pathways in fibrotic disease will accelerate development of novel therapeutic strategies that target HIF-1?. Such new therapeutic strategies may be particularly effective for treatment of the prototypic, multisystem fibrotic, autoimmune disease SSc. äTargeting Hypoxia Inducible Factors-1? As a Novel Therapy in Fibrosis (epmc).pdf DeepDyve Pubget Overpricing